[NT 10-Q] HCW Biologics Inc. SEC Filing
HCW Biologics Inc. submitted a Form NT for its periodic report covering the period ended June 30, 2025, notifying the SEC that its Form 10-Q will be filed within the five-day grace period under Rule 12b-25. The notice identifies a prior quarter arbitration as the driver of materially higher legal costs in Q2 2024: $10.4 million of legal fees in Q2 2024 versus $142,452 in the same period of 2025, and states the arbitration was settled on July 13, 2024. The company lists Rebecca Byam, Chief Financial Officer, as the contact for the notification. The registrant indicates all other periodic reports required over the prior 12 months have been filed.
HCW Biologics Inc. ha presentato un Form NT relativo al rapporto periodico per il periodo conclusosi il 30 giugno 2025, informando la SEC che il suo Form 10-Q sar脿 depositato entro il periodo di tolleranza di cinque giorni previsto dalla Rule 12b-25. L鈥檃vviso indica che un arbitrato relativo a un trimestre precedente ha determinato costi legali significativamente pi霉 elevati nel secondo trimestre del 2024: 10,4 milioni di dollari di spese legali nel Q2 2024 rispetto a 142.452 nello stesso periodo del 2025, e specifica che l鈥檃rbitrato 猫 stato risolto il 13 luglio 2024. La societ脿 segnala Rebecca Byam, Chief Financial Officer, come contatto per la notifica. Il registrante dichiara che tutti gli altri rapporti periodici richiesti nei precedenti 12 mesi sono stati presentati.
HCW Biologics Inc. present贸 un Form NT para su informe peri贸dico relativo al per铆odo terminado el 30 de junio de 2025, notificando a la SEC que su Form 10-Q se presentar谩 dentro del per铆odo de gracia de cinco d铆as seg煤n la Regla 12b-25. El aviso se帽ala que un arbitraje de un trimestre anterior fue la causa de costos legales materialmente m谩s altos en el segundo trimestre de 2024: 10,4 millones de d贸lares en honorarios legales en el Q2 2024 frente a 142.452 en el mismo periodo de 2025, y afirma que el arbitraje se resolvi贸 el 13 de julio de 2024. La compa帽铆a designa a Rebecca Byam, Chief Financial Officer, como contacto para la notificaci贸n. El registrante indica que todos los dem谩s informes peri贸dicos requeridos en los 煤ltimos 12 meses han sido presentados.
HCW Biologics Inc.電� 2025雲� 6鞗� 30鞚�搿� 膦呺霅橂姅 旮瓣皠鞐� 雽�頃� 鞝曣赴氤搓碃靹� 鞝滌稖 歆�鞐办潉 鞎岆Μ電� Form NT毳� 鞝滌稖頄堨溂氅�, Form 10-Q電� Rule 12b-25鞐� 霐半ジ 5鞚� 鞙犾槇 旮瓣皠 雮挫棎 鞝滌稖霅� 瓴冹澊霛缄碃 SEC鞐� 韱奠頄堨姷雼堧嫟. 瓿奠電� 鞚挫爠 攵勱赴 欷� 頃橂倶鞚� 欷戩灛(arbitration)臧� 2024雲� 2攵勱赴鞐� 氩曤牍勳毄鞚� 韥矊 歃濌皜鞁滍偍 鞗愳澑鞛勳潉 氚濏瀳瓿� 鞛堨姷雼堧嫟: 2024雲� 2攵勱赴 氩曤牍勳毄鞚� 1,040毵� 雼煬鞚� 氚橂┐ 2025雲� 霃欔赴臧勳棎電� 142,452雼煬鞓�鞙茧┌, 頃措嫻 欷戩灛電� 2024雲� 7鞗� 13鞚�鞐� 頃╈潣搿� 膦呹舶霅橃棃雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 須岇偓電� 鞚� 韱奠鞚� 鞐半澖觳橂 斓滉碃鞛毂呾瀯鞛�(CFO)鞚� Rebecca Byam鞚� 旮办灛頄堨姷雼堧嫟. 霌彪旮瓣磤鞚� 歆�雮� 12臧滌洈 霃欖晥 鞖旉惮霅� 雼るジ 氇摖 鞝曣赴氤搓碃靹滊姅 鞝滌稖霅橃棃雼り碃 氚濏様鞀惦媹雼�.
HCW Biologics Inc. a d茅pos茅 un Form NT pour son rapport p茅riodique couvrant la p茅riode close le 30 juin 2025, informant la SEC que son Form 10-Q sera d茅pos茅 dans le d茅lai de gr芒ce de cinq jours pr茅vu par la Rule 12b-25. L鈥檃vis pr茅cise qu鈥檜n arbitrage d鈥檜n trimestre ant茅rieur a entra卯n茅 des frais juridiques sensiblement plus 茅lev茅s au T2 2024 : 10,4 millions de dollars d鈥檋onoraires juridiques au T2 2024 contre 142 452 pour la m锚me p茅riode en 2025, et indique que l鈥檃rbitrage a 茅t茅 r茅gl茅 le 13 juillet 2024. La soci茅t茅 d茅signe Rebecca Byam, directrice financi猫re (CFO), comme personne de contact pour la notification. Le d茅posant indique que tous les autres rapports p茅riodiques requis au cours des 12 derniers mois ont 茅t茅 d茅pos茅s.
HCW Biologics Inc. reichte ein Form NT f眉r den Periodenbericht zum 30. Juni 2025 ein und teilte der SEC mit, dass das Form 10-Q innerhalb der f眉nft盲gigen Nachfrist gem盲脽 Rule 12b-25 eingereicht wird. Die Mitteilung nennt ein Schiedsverfahren aus einem fr眉heren Quartal als Ursache f眉r die deutlich h枚heren Rechtskosten im 2. Quartal 2024: 10,4 Mio. USD an Anwaltskosten im Q2 2024 gegen眉ber 142.452 USD im gleichen Zeitraum 2025, und gibt an, dass das Schiedsverfahren am 13. Juli 2024 beigelegt wurde. Als Kontakt f眉r die Mitteilung wird Rebecca Byam, Chief Financial Officer, angegeben. Der Registrant erkl盲rt, dass alle anderen in den letzten 12 Monaten geforderten Periodenberichte eingereicht wurden.
- Transparent disclosure of the late filing using Form NT and identification of the Rule 12b-25 grace period
- Quantified material one-time legal expense for Q2 2024 ($10.4 million) and clear comparison to Q2 2025 ($142,452), improving clarity
- All other periodic reports affirmed filed for the prior 12 months, indicating routine compliance apart from this NT
- Failure to timely file the Form 10-Q triggered a Form NT, raising procedural and control concerns
- Material one-time legal charge in Q2 2024 may have materially impacted prior-period results, complicating year-over-year comparisons
- Limited financial information in the notice prevents assessment of impact on liquidity, covenants, or ongoing operations
Insights
TL;DR: A late 10-Q notice tied to sharp year-over-year legal expense swing; operational results otherwise not provided.
The Form NT discloses a late filing remedied under Rule 12b-25 and quantifies a large one-time legal expense in Q2 2024 of $10.4 million versus $142,452 in Q2 2025, attributable to an arbitration that settled July 13, 2024. This indicates the company incurred a material, non-recurring charge in the prior-year quarter that likely depressed Q2 2024 results but is not expected to recur at the same scale. No revenue, net income, cash balance, or other operating metrics are included, so impact on liquidity or covenants cannot be assessed from this notice alone.
TL;DR: Disclosure is straightforward but raises governance questions about controls that delayed filing.
The registrant properly used Form NT to notify the SEC and provided a specific explanation for the prior quarter's elevated legal costs tied to arbitration. While the company affirms other required reports were filed, the NT suggests a procedural or substantive issue that delayed the 10-Q. Management identified a named contact (CFO) and quantified the legal expense difference, which supports transparency. The filing lacks detail on internal controls or remediation steps for the delay.
HCW Biologics Inc. ha presentato un Form NT relativo al rapporto periodico per il periodo conclusosi il 30 giugno 2025, informando la SEC che il suo Form 10-Q sar脿 depositato entro il periodo di tolleranza di cinque giorni previsto dalla Rule 12b-25. L鈥檃vviso indica che un arbitrato relativo a un trimestre precedente ha determinato costi legali significativamente pi霉 elevati nel secondo trimestre del 2024: 10,4 milioni di dollari di spese legali nel Q2 2024 rispetto a 142.452 nello stesso periodo del 2025, e specifica che l鈥檃rbitrato 猫 stato risolto il 13 luglio 2024. La societ脿 segnala Rebecca Byam, Chief Financial Officer, come contatto per la notifica. Il registrante dichiara che tutti gli altri rapporti periodici richiesti nei precedenti 12 mesi sono stati presentati.
HCW Biologics Inc. present贸 un Form NT para su informe peri贸dico relativo al per铆odo terminado el 30 de junio de 2025, notificando a la SEC que su Form 10-Q se presentar谩 dentro del per铆odo de gracia de cinco d铆as seg煤n la Regla 12b-25. El aviso se帽ala que un arbitraje de un trimestre anterior fue la causa de costos legales materialmente m谩s altos en el segundo trimestre de 2024: 10,4 millones de d贸lares en honorarios legales en el Q2 2024 frente a 142.452 en el mismo periodo de 2025, y afirma que el arbitraje se resolvi贸 el 13 de julio de 2024. La compa帽铆a designa a Rebecca Byam, Chief Financial Officer, como contacto para la notificaci贸n. El registrante indica que todos los dem谩s informes peri贸dicos requeridos en los 煤ltimos 12 meses han sido presentados.
HCW Biologics Inc.電� 2025雲� 6鞗� 30鞚�搿� 膦呺霅橂姅 旮瓣皠鞐� 雽�頃� 鞝曣赴氤搓碃靹� 鞝滌稖 歆�鞐办潉 鞎岆Μ電� Form NT毳� 鞝滌稖頄堨溂氅�, Form 10-Q電� Rule 12b-25鞐� 霐半ジ 5鞚� 鞙犾槇 旮瓣皠 雮挫棎 鞝滌稖霅� 瓴冹澊霛缄碃 SEC鞐� 韱奠頄堨姷雼堧嫟. 瓿奠電� 鞚挫爠 攵勱赴 欷� 頃橂倶鞚� 欷戩灛(arbitration)臧� 2024雲� 2攵勱赴鞐� 氩曤牍勳毄鞚� 韥矊 歃濌皜鞁滍偍 鞗愳澑鞛勳潉 氚濏瀳瓿� 鞛堨姷雼堧嫟: 2024雲� 2攵勱赴 氩曤牍勳毄鞚� 1,040毵� 雼煬鞚� 氚橂┐ 2025雲� 霃欔赴臧勳棎電� 142,452雼煬鞓�鞙茧┌, 頃措嫻 欷戩灛電� 2024雲� 7鞗� 13鞚�鞐� 頃╈潣搿� 膦呹舶霅橃棃雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 須岇偓電� 鞚� 韱奠鞚� 鞐半澖觳橂 斓滉碃鞛毂呾瀯鞛�(CFO)鞚� Rebecca Byam鞚� 旮办灛頄堨姷雼堧嫟. 霌彪旮瓣磤鞚� 歆�雮� 12臧滌洈 霃欖晥 鞖旉惮霅� 雼るジ 氇摖 鞝曣赴氤搓碃靹滊姅 鞝滌稖霅橃棃雼り碃 氚濏様鞀惦媹雼�.
HCW Biologics Inc. a d茅pos茅 un Form NT pour son rapport p茅riodique couvrant la p茅riode close le 30 juin 2025, informant la SEC que son Form 10-Q sera d茅pos茅 dans le d茅lai de gr芒ce de cinq jours pr茅vu par la Rule 12b-25. L鈥檃vis pr茅cise qu鈥檜n arbitrage d鈥檜n trimestre ant茅rieur a entra卯n茅 des frais juridiques sensiblement plus 茅lev茅s au T2 2024 : 10,4 millions de dollars d鈥檋onoraires juridiques au T2 2024 contre 142 452 pour la m锚me p茅riode en 2025, et indique que l鈥檃rbitrage a 茅t茅 r茅gl茅 le 13 juillet 2024. La soci茅t茅 d茅signe Rebecca Byam, directrice financi猫re (CFO), comme personne de contact pour la notification. Le d茅posant indique que tous les autres rapports p茅riodiques requis au cours des 12 derniers mois ont 茅t茅 d茅pos茅s.
HCW Biologics Inc. reichte ein Form NT f眉r den Periodenbericht zum 30. Juni 2025 ein und teilte der SEC mit, dass das Form 10-Q innerhalb der f眉nft盲gigen Nachfrist gem盲脽 Rule 12b-25 eingereicht wird. Die Mitteilung nennt ein Schiedsverfahren aus einem fr眉heren Quartal als Ursache f眉r die deutlich h枚heren Rechtskosten im 2. Quartal 2024: 10,4 Mio. USD an Anwaltskosten im Q2 2024 gegen眉ber 142.452 USD im gleichen Zeitraum 2025, und gibt an, dass das Schiedsverfahren am 13. Juli 2024 beigelegt wurde. Als Kontakt f眉r die Mitteilung wird Rebecca Byam, Chief Financial Officer, angegeben. Der Registrant erkl盲rt, dass alle anderen in den letzten 12 Monaten geforderten Periodenberichte eingereicht wurden.
FAQ
Why did HCWB file a Form NT instead of a Form 10-Q for period ended June 30, 2025?
What caused the large year-over-year change in legal expenses reported by HCWB?
Has HCW Biologics filed its other required periodic reports?
Who is the contact for questions about HCWB's Form NT?
Does the Form NT disclose effects on HCWB's liquidity or covenants?
